e10vq
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(MARK ONE)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 |
FOR THE QUARTERLY PERIOD ENDED March 31, 2007
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 |
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER 1-11151
U.S. PHYSICAL THERAPY, INC.
(NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
|
|
|
NEVADA
|
|
76-0364866 |
(STATE OR OTHER JURISDICTION OF
|
|
(I.R.S. EMPLOYER |
INCORPORATION OR ORGANIZATION)
|
|
IDENTIFICATION NO.) |
|
|
|
1300 WEST SAM HOUSTON PARKWAY SOUTH, SUITE 300,
|
|
77042 |
HOUSTON, TEXAS
|
|
(ZIP CODE) |
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) |
|
|
REGISTRANTS TELEPHONE NUMBER, INCLUDING AREA CODE: (713) 297-7000
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
þ Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in
Rule 12b-2 of the Exchange Act. (Check One):
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer þ
|
|
Non-accelerated filer o |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act).
o Yes þ No
As of May 8, 2007, the number of shares outstanding (issued less treasury stock) of the
registrants common stock, par value $.01 per share, was:
11,547,112.
ITEM 1. FINANCIAL STATEMENTS.
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE DATA)
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2007 |
|
|
2006 |
|
|
|
(unaudited) |
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
13,093 |
|
|
$ |
10,952 |
|
Marketable securities available for sale |
|
|
1,460 |
|
|
|
500 |
|
Patient accounts receivable, less allowance for doubtful
accounts of $1,669 and $1,567, respectively |
|
|
21,873 |
|
|
|
21,503 |
|
Accounts receivable other |
|
|
602 |
|
|
|
775 |
|
Other current assets |
|
|
2,067 |
|
|
|
2,251 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
39,095 |
|
|
|
35,981 |
|
|
|
|
|
|
|
|
|
|
Fixed assets: |
|
|
|
|
|
|
|
|
Furniture and equipment |
|
|
24,098 |
|
|
|
23,718 |
|
Leasehold improvements |
|
|
15,554 |
|
|
|
15,226 |
|
|
|
|
|
|
|
|
|
|
|
39,652 |
|
|
|
38,944 |
|
Less accumulated depreciation and amortization |
|
|
26,618 |
|
|
|
25,573 |
|
|
|
|
|
|
|
|
|
|
|
13,034 |
|
|
|
13,371 |
|
Goodwill |
|
|
21,082 |
|
|
|
20,997 |
|
Other assets |
|
|
1,591 |
|
|
|
1,108 |
|
|
|
|
|
|
|
|
|
|
$ |
74,802 |
|
|
$ |
71,457 |
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable trade |
|
$ |
1,059 |
|
|
$ |
1,601 |
|
Accrued expenses |
|
|
9,031 |
|
|
|
7,007 |
|
Current portion of notes payable |
|
|
537 |
|
|
|
562 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
10,627 |
|
|
|
9,170 |
|
Notes payable |
|
|
656 |
|
|
|
797 |
|
Deferred rent |
|
|
1,239 |
|
|
|
1,273 |
|
Other long-term liabilities |
|
|
717 |
|
|
|
829 |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
13,239 |
|
|
|
12,069 |
|
|
|
|
|
|
|
|
|
|
Minority interests in subsidiary limited partnerships |
|
|
3,723 |
|
|
|
3,871 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders equity: |
|
|
|
|
|
|
|
|
Preferred stock, $.01 par value, 500,000 shares authorized,
no shares issued and outstanding |
|
|
|
|
|
|
|
|
Common stock, $.01 par value, 20,000,000 shares authorized,
13,750,849 and 13,681,849, shares issued, respectively |
|
|
138 |
|
|
|
137 |
|
Additional paid-in capital |
|
|
36,797 |
|
|
|
36,304 |
|
Retained earnings |
|
|
52,533 |
|
|
|
50,704 |
|
Treasury stock at cost, 2,214,737 shares |
|
|
(31,628 |
) |
|
|
(31,628 |
) |
|
|
|
|
|
|
|
Total shareholders equity |
|
|
57,840 |
|
|
|
55,517 |
|
|
|
|
|
|
|
|
|
|
$ |
74,802 |
|
|
$ |
71,457 |
|
|
|
|
|
|
|
|
See notes to consolidated financial statements.
3
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF NET INCOME
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2007 |
|
|
2006 |
|
Net patient revenues |
|
$ |
34,276 |
|
|
$ |
32,908 |
|
Management contract revenues |
|
|
318 |
|
|
|
569 |
|
Other revenues |
|
|
26 |
|
|
|
26 |
|
|
|
|
|
|
|
|
Net revenues |
|
|
34,620 |
|
|
|
33,503 |
|
|
|
|
|
|
|
|
|
|
Clinic operating costs: |
|
|
|
|
|
|
|
|
Salaries and related costs |
|
|
17,916 |
|
|
|
17,287 |
|
Rent, clinic supplies, contract labor and other |
|
|
7,429 |
|
|
|
7,013 |
|
Provision for doubtful accounts |
|
|
631 |
|
|
|
532 |
|
|
|
|
|
|
|
|
|
|
|
25,976 |
|
|
|
24,832 |
|
|
|
|
|
|
|
|
|
|
Corporate office costs |
|
|
4,357 |
|
|
|
4,515 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income from continuing operations |
|
|
4,287 |
|
|
|
4,156 |
|
|
|
|
|
|
|
|
|
|
Interest and investment income, net |
|
|
41 |
|
|
|
82 |
|
Loss in unconsolidated joint venture |
|
|
|
|
|
|
(21 |
) |
Minority interests in subsidiary limited partnerships |
|
|
(1,315 |
) |
|
|
(1,469 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes from continuing operations |
|
|
3,013 |
|
|
|
2,748 |
|
Provision for income taxes |
|
|
1,169 |
|
|
|
1,042 |
|
|
|
|
|
|
|
|
Net income from continuing operations |
|
|
1,844 |
|
|
|
1,706 |
|
|
|
|
|
|
|
|
|
|
Discontinued operations: |
|
|
|
|
|
|
|
|
(Loss) income from discontinued operations |
|
|
(24 |
) |
|
|
(338 |
) |
Tax benefit (expense) from discontinued operations |
|
|
9 |
|
|
|
116 |
|
|
|
|
|
|
|
|
|
|
|
(15 |
) |
|
|
(222 |
) |
|
|
|
|
|
|
|
Net income |
|
$ |
1,829 |
|
|
$ |
1,484 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share: |
|
|
|
|
|
|
|
|
Basic income from continuing operations |
|
$ |
0.16 |
|
|
$ |
0.14 |
|
Basic (loss) income from discontinued operations |
|
|
(0.00 |
) |
|
|
(0.01 |
) |
|
|
|
|
|
|
|
Total basic earnings per common share |
|
$ |
0.16 |
|
|
$ |
0.13 |
|
|
|
|
|
|
|
|
Diluted income from continuing operations |
|
$ |
0.16 |
|
|
$ |
0.14 |
|
Diluted (loss) income from discontinued operations |
|
|
(0.00 |
) |
|
|
(0.02 |
) |
|
|
|
|
|
|
|
Total diluted earnings per common share |
|
$ |
0.16 |
|
|
$ |
0.12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computation: |
|
|
|
|
|
|
|
|
Basic earnings per common share |
|
|
11,501 |
|
|
|
11,824 |
|
|
|
|
|
|
|
|
Diluted earnings per common share |
|
|
11,589 |
|
|
|
12,036 |
|
|
|
|
|
|
|
|
See notes to consolidated financial statements.
4
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2007 |
|
|
2006 |
|
OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
Net income |
|
$ |
1,829 |
|
|
$ |
1,484 |
|
Adjustments to reconcile net income to net cash provided by
operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
1,125 |
|
|
|
1,090 |
|
Minority interests in earnings of subsidiary limited partnerships |
|
|
1,315 |
|
|
|
1,444 |
|
Provision for doubtful accounts |
|
|
631 |
|
|
|
566 |
|
Equity-based awards compensation expense |
|
|
257 |
|
|
|
222 |
|
Loss on sale or abandonment of assets |
|
|
6 |
|
|
|
12 |
|
Tax benefit from exercise of stock options |
|
|
(9 |
) |
|
|
(10 |
) |
Recognition of deferred rent subsidies |
|
|
(130 |
) |
|
|
(103 |
) |
Deferred income taxes |
|
|
81 |
|
|
|
471 |
|
Changes in operating assets and liabilites: |
|
|
|
|
|
|
|
|
Increase in patient account receivable |
|
|
(1,001 |
) |
|
|
(1,218 |
) |
(Increase) decrease in accounts receivable other |
|
|
173 |
|
|
|
(137 |
) |
Increase in other assets |
|
|
(396 |
) |
|
|
(107 |
) |
Increase in accounts payable and accrued expenses |
|
|
1,526 |
|
|
|
1,313 |
|
(Decrease) increase in other liabilities |
|
|
(7 |
) |
|
|
103 |
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
5,400 |
|
|
|
5,130 |
|
|
|
|
|
|
|
|
|
|
INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
Purchase of fixed assets |
|
|
(784 |
) |
|
|
(1,480 |
) |
Purchase of business |
|
|
|
|
|
|
(54 |
) |
Acquisitions of minority interest, included in goodwill |
|
|
(129 |
) |
|
|
(800 |
) |
Purchase of marketable securities available for sale |
|
|
(1,600 |
) |
|
|
(100 |
) |
Proceeds on sale of marketable securities available for sale |
|
|
640 |
|
|
|
|
|
Proceeds on sale of fixed assets |
|
|
6 |
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(1,867 |
) |
|
|
(2,434 |
) |
|
|
|
|
|
|
|
|
|
FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Distributions to minority investors in subsidiary limited partnerships |
|
|
(1,463 |
) |
|
|
(1,030 |
) |
Repurchase of common stock |
|
|
|
|
|
|
(860 |
) |
Payment of notes payable |
|
|
(166 |
) |
|
|
(68 |
) |
Excess tax benefit from stock options exercised |
|
|
9 |
|
|
|
10 |
|
Proceeds from exercise of stock options |
|
|
228 |
|
|
|
11 |
|
|
|
|
|
|
|
|
Net cash used in financing activities |
|
|
(1,392 |
) |
|
|
(1,937 |
) |
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
|
|
2,141 |
|
|
|
759 |
|
Cash and cash equivalents beginning of period |
|
|
10,952 |
|
|
|
12,352 |
|
|
|
|
|
|
|
|
Cash and cash equivalents end of period |
|
$ |
13,093 |
|
|
$ |
13,111 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION |
|
|
|
|
|
|
|
|
Cash paid during the period for : |
|
|
|
|
|
|
|
|
Income taxes |
|
$ |
109 |
|
|
$ |
256 |
|
Interest |
|
$ |
29 |
|
|
$ |
11 |
|
See notes to consolidated financial statements.
5
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY
(IN THOUSANDS)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
Common Stock |
|
|
Paid-In |
|
|
Retained |
|
|
Treasury Stock |
|
|
Shareholders |
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Earnings |
|
|
Shares |
|
|
Amount |
|
|
Equity |
|
Balance December 31, 2006 |
|
|
13,682 |
|
|
$ |
137 |
|
|
$ |
36,304 |
|
|
$ |
50,704 |
|
|
|
(2,215 |
) |
|
$ |
(31,628 |
) |
|
$ |
55,517 |
|
Proceeds from exercise of stock options |
|
|
18 |
|
|
|
1 |
|
|
|
227 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
228 |
|
Tax benefit from exercise of
stock options |
|
|
|
|
|
|
|
|
|
|
9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9 |
|
Issuance of restricted stock |
|
|
51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of restricted stock |
|
|
|
|
|
|
|
|
|
|
21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21 |
|
Equity-based compensation expense |
|
|
|
|
|
|
|
|
|
|
236 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
236 |
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,829 |
|
|
|
|
|
|
|
|
|
|
|
1,829 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance March 31, 2007 |
|
|
13,751 |
|
|
$ |
138 |
|
|
$ |
36,797 |
|
|
$ |
52,533 |
|
|
|
(2,215 |
) |
|
$ |
(31,628 |
) |
|
$ |
57,840 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to consolidated financial statements.
6
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2007
(unaudited)
1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
The consolidated financial statements include the accounts of U.S. Physical Therapy, Inc. and its
subsidiaries. All significant intercompany transactions and balances have been eliminated. The
Company primarily operates through subsidiary clinic partnerships, in which the Company generally
owns a 1% general partnership interest and a 64% limited partnership interest. The managing
therapist of each clinic owns the remaining limited partnership interest in the majority of the
clinics (hereinafter referred to as Clinic Partnership). To a lesser extent, the Company
operates some clinics, through wholly-owned subsidiaries, under profit sharing arrangements with
therapists (hereinafter referred to as Wholly-Owned Facilities).
We continue to seek to attract physical and occupational therapists who have established
relationships with physicians by offering therapists a competitive salary and a share of the
profits of the clinic operated by that therapist. In addition, we have developed satellite clinic
facilities of existing clinics, with the result that many clinic groups operate more than one
clinic location. During the quarter ended March 31, 2007, we opened three new clinics and closed
two, therefore, ending the quarter with 293 clinics. In 2007, we intend to continue to focus on
developing new clinics and on opening satellite clinics where deemed appropriate. We also continue
to evaluate acquisition opportunities.
The accompanying unaudited consolidated financial statements were prepared in accordance with
accounting principles generally accepted in the United States of America for interim financial
information and in accordance with the instructions for Form 10-Q. However, the statements do not
include all of the information and footnotes required by accounting principles generally accepted
in the United States of America for complete financial statements. For further information
regarding the Companys accounting policies, please read the audited financial statements included
in the Companys Form 10-K for the year ended December 31, 2006.
The Company believes, and the Chief Executive Officer, Chief Financial Officer and Corporate
Controller have certified, that the financial statements included in this report contain all
necessary adjustments (consisting only of normal recurring adjustments) to present fairly, in all
material respects, the Companys financial position, results of operations and cash flows for the
interim periods presented.
Operating results for the three months ended March 31, 2007 are not necessarily indicative of the
results the Company expects for the entire year. Please also review the Risk Factors section
included in our Form 10-K for the year ended December 31, 2006.
Clinic Partnerships
For Clinic Partnerships, the earnings and liabilities attributable to the minority limited
partnership interest, typically owned by the managing therapist, are recorded within the balance
sheets and income statements as minority interests in subsidiary limited partnerships.
Wholly-Owned Facilities
For Wholly-Owned Facilities with profit sharing arrangements, an appropriate accrual is recorded
for the amount of profit sharing due the profit sharing therapists. The amount is expensed as
compensation and included in clinic operating costs salaries and related costs. The respective
liability is included in current liabilities accrued expenses on the balance sheet.
Significant Accounting Policies
Cash Equivalents
The Company considers all highly liquid investments with an original maturity or remaining maturity
at the time of purchase of three months or less to be cash equivalents. Based upon its investment
policy, the Company invests its cash primarily in deposits with major financial institutions, in
highly rated commercial paper, short-term United States treasury obligations, United States and
municipal government agency securities and United States government sponsored enterprises. The
Company held approximately $8.3 million and $4.2 million in highly liquid investments included in
cash and cash equivalents at March 31, 2007 and December 31, 2006, respectively.
7
The Company maintains its cash and cash equivalents at financial institutions. The combined
account balances at several institutions typically exceed Federal Deposit Insurance Corporation
(FDIC) insurance coverage and, as a result, there is a concentration of credit risk related to
amounts on deposit in excess of FDIC insurance coverage. Management believes this risk is not
significant.
Marketable Securities
Management determines the appropriate classification of its investments at the time of purchase and
reevaluates such determination at each balance sheet date. As of March 31, 2007 and December 31,
2006, all marketable securities were classified as available for sale. Available-for-sale
securities are carried at fair value, with unrealized holding gains and losses, net of tax,
reported as a separate component of shareholders equity. Since the fair value of the marketable
securities available for sale equals the cost basis for such securities, there is no effect on
comprehensive income for the periods reported.
Long-Lived Assets
Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the
estimated useful lives of the related assets. Estimated useful lives for furniture and equipment
range from three to eight years. Leasehold improvements are amortized over the shorter of the
related lease term or estimated useful lives of the assets, which is generally three to five years.
Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of
The Company reviews property and equipment and intangible assets with finite lives for impairment
upon the occurrence of certain events or circumstances which indicate that the related amounts may
be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair
value less costs to sell.
Goodwill
Goodwill represents the excess of costs over the fair value of the acquired business assets.
Historically, goodwill has been derived from the purchase of some or all of a particular local
managements equity interest in an existing clinic or from acquisitions.
The fair value of goodwill and other intangible assets with indefinite lives are tested for
impairment annually and upon the occurrence of certain events, and are written down to fair value
if considered impaired. The Company evaluates goodwill for impairment on an annual basis (in its
third quarter) by comparing the fair value of each reporting unit to the carrying value of the
reporting unit including related goodwill. A reporting unit refers to the acquired interest of a
single clinic or group of clinics. Local management typically continues to manage the acquired
clinic or group of clinics on behalf of the Company. For each clinic or group of clinics, the
Company maintains discrete financial information and both corporate and local management regularly
review the operating results. For each purchase of the equity interest, goodwill is assigned to
the respective clinic or group of clinics, if deemed appropriate.
Revenue Recognition
Revenues are recognized in the period in which services are rendered. Net patient revenues (patient
revenues less estimated contractual adjustments) are reported at the estimated net realizable
amounts from insurance companies, third-party payors, patients and others for services rendered.
The Company has agreements with third-party payors that provide for payments to the Company at
amounts different from its established rates. The allowance for estimated contractual adjustments
is based on terms of payor contracts and historical collection and write-off experience.
The Company determines allowances for doubtful accounts based on the specific agings and payor
classifications at each clinic. The provision for doubtful accounts is included in clinic
operating costs in the statement of net income. Net accounts receivable, which are stated at the
historical carrying amount net of contractual allowances, write-offs and allowance for doubtful
accounts, includes only those amounts the Company estimates to be collectible.
Since 1999, reimbursement for outpatient therapy services has been made according to a fee schedule
published by the Department of Health and Human Services (HHS). Under the Balanced Budget Act of
1997, the total amount paid by Medicare in any one year for outpatient physical and/or occupational
therapy (including speech-language pathology) to any one patient was initially limited to $1,500
(the Medicare Cap or Limit), except for services provided in hospitals. After a three-year
moratorium, this Medicare Limit on therapy services was implemented for services rendered on or
after September 1, 2003 subject to an adjusted total of $1,590 (the Adjusted Medicare Limit).
Effective December 8, 2003, a
8
moratorium was again placed on the Adjusted Medicare Limit for the remainder of 2003 and for years
2004 and 2005. Under the Medicare Prescription Drug, Improvement and Modernization Act of 2003,
the Adjusted Medicare Limit was reinstated effective as of January 1, 2006. Outpatient therapy
services rendered to Medicare beneficiaries by the Companys therapists are subject to the cap,
except to the extent these services are rendered pursuant to certain management and professional
services agreements with inpatient facilities, in which case the caps do not apply. The Medicare
Limit for 2006 was $1,740.
In 2006, Congress passed the Deficit Reduction Act (DRA), which allowed the Centers for Medicare
and Medicaid Services (CMS) to grant exceptions to the Medicare Cap for services provided during
the year, as long as those services met certain qualifications (as more fully defined in the
February 15, 2006 Medicare Fact Sheet). The exception process allowed for automatic and manual
exceptions to the Medicare Cap for medically necessary services. The exception process specified
diagnosis that qualified for an automatic exception to the Medicare Cap if the condition or
complexity has a direct and significant impact on the course of therapy being provided and the
additional treatment was medically necessary. The exception process further provided that manual
exceptions could be granted if the condition or complexity did not allow for an automatic
exception, but was believed to require medically necessary services. This exception process
adopted as part of the DRA was scheduled to expire on December 31, 2006.
In December 2006, Congress passed and the President signed the Tax Relief and Health Care Act of
2006, which extends the Medicare Cap exceptions process for 2007. The Medicare Cap continues to
apply in 2007, and the Adjusted Medicare Limit for 2007 is $1,780. After Congress extended the
exceptions process for another year, CMS revised the exceptions procedures. These procedures
eliminate the manual exceptions process and expand the use of automatic exceptions. Thus, as of
January 1, 2007, all services that require exceptions to the Medicare Cap are processed as
automatic exceptions. While the basic procedure for obtaining an automatic exception remains the
same, CMS expanded requirements for documentation related to the medical necessity of services
provided above the cap.
Since the Medicare Cap was implemented, patients who have been impacted by the cap and those who do
not qualify for an exception may choose to pay for services in excess of the cap themselves;
however, it is assumed that the Medicare Cap will continue to result in lost revenues to the
Company.
Laws and regulations governing the Medicare program are complex and subject to interpretation. The
Company believes that it is in compliance in all material respects with all applicable laws and
regulations and is not aware of any pending or threatened investigations involving allegations of
potential wrongdoing that would have a material effect on the Companys financial statements as of
March 31, 2007. Compliance with such laws and regulations can be subject to future government
review and interpretation, as well as significant regulatory action including fines, penalties, and
exclusion from the Medicare program.
Contractual Allowances
Contractual allowances result from the differences between the rates charged for services performed
and expected reimbursements by both insurance companies and government sponsored healthcare
programs for such services. Medicare regulations and the various third party payors and managed
care contracts are often complex and may include multiple reimbursement mechanisms payable for the
services provided in Company clinics. The Company estimates contractual allowances based on our
interpretation of the applicable regulations, payor contracts and historical calculations. Each
month the Company estimates its contractual allowance for each clinic based on payor contracts and
the historical collection experience of the clinic and applies an appropriate contractual allowance
reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based
on the Companys historical experience, calculating the contractual allowance reserve percentage at
the payor level is sufficient to allow us to provide the necessary detail and accuracy with its
collectibility estimates. However, the services authorized and provided and related reimbursement
are subject to interpretation that could result in payments that differ from our estimates. Payor
terms are periodically revised necessitating continual review and assessment of the estimates made
by management. The Companys billing system does not capture the exact change in our contractual
allowance reserve estimate from period to period in order to assess the accuracy of our revenues
and hence our contractual allowance reserves. Management regularly compares its cash collections to
corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the
aggregate, historically the difference between net revenues and corresponding cash collections has
generally been less than 1% of net revenues. Additionally, analysis of subsequent periods
contractual write-offs on a payor basis shows a less than 1% difference between the actual
aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve
percentage associated with the same period end balance. As a result, we believe that a reasonable
likely change in the contractual allowance reserve estimate would not likely be more than 1% at
March 31, 2007.
9
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and
liabilities are recognized for the future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax
bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the period that includes the
enactment date.
In June 2006, the FASB issued FIN 48, Accounting for Uncertainty in Income Taxesan interpretation
of FASB Statement No. 109, Accounting for Income Taxes. FIN 48 prescribes a model for how a company
is to recognize, measure, present and disclose in its financial statements uncertain positions that
a company has taken or plans to take on a future tax return. Under FIN 48, the Company may
recognize the tax benefit from an uncertain tax position only if it is more likely than not that
the tax position will be sustained on examination by the taxing authorities, based on the technical
merits of the position. The tax benefits recognized in the financial statements from such a
position should be measured based on the largest benefit that has a greater than fifty percent
likelihood of being realized upon ultimate settlement. FIN 48 also provides guidance on
derecognition, classification, interest and penalties on income taxes, accounting in interim
periods and requires increased disclosures. The Company adopted the provisions of FIN 48 on January
1, 2007. As a result of the implementation of FIN 48, the Company did not have any unrecognized tax
benefits and there was no effect on our financial condition or results of operations as a result of
implementing FIN 48.
The Company did not have any unrecognized tax benefits for Federal, state and local tax
jurisdictions. As a result there was no effect on our financial condition or results of operations
as a result of implementing FIN 48 as of March 31, 2007.
Estimated interest and penalties related to potential underpayment on any unrecognized tax benefits
are to be classified as a component of tax expense in the Consolidated Statement of Operations. As
of the date of adoption of FIN 48, the Company did not have any accrued interest or penalties
associated with any unrecognized tax benefits, nor was any interest expense recognized during the
quarter.
Fair Values of Financial Instruments
The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts
receivable, accounts payable and notes payable approximate their fair values due to the short-term
maturity of these financial instruments. The carrying amounts for marketable securities
available for sale approximate the fair value on the respective balance sheet dates.
Segment Reporting
Operating segments are components of an enterprise for which separate financial information is
available that is evaluated regularly by chief operating decision makers in deciding how to
allocate resources and in assessing performance. The Company identifies operating segments based
on management responsibility and believes it meets the criteria for aggregating its operating
segments into a single reporting segment.
Use of Estimates
In preparing the Companys consolidated financial statements, management makes certain estimates
and assumptions that affect the amounts reported in the consolidated financial statements and
related disclosures. Actual results may differ from these estimates.
Self-Insurance Program
The Company utilizes a self-insurance plan for its employee group health insurance coverage
administered by a third party. Predetermined loss limits have been arranged with the insurance
company to limit the Companys maximum liability and cash outlay. Accrued expenses include the
estimated incurred but unreported costs to settle unpaid claims and estimated future claims.
10
Reclassifications
In accordance with Statement of Financial Accounting Standards (SFAS) No. 154, Accounting
Changes and Error Corrections A Replacement of APB Opinion No. 20 and FASB Statement No. 3, the
prior period financial statements have been reclassified to conform with the current year
presentation of reporting all earnings allocated to the minority limited partners within the line
item in the balance sheets and income statements entitled minority interests in subsidiary
limited partnerships. The earnings allocated to the minority limited partners are shown as an
adjustment to net income in the statements of cash flows. The payments of the distributions
related to these allocated earnings are shown as use of cash in the financing activities section of
the statement of cash flows. In prior years, based upon an interpretation of the Emerging Issues
Task Force issue 00-23, Issues Related to the Accounting for Stock Compensation under APB No. 25
and FASB Interpretation No. 44, the Company reported the earnings allocated to minority limited
partners for partnerships formed after January 18, 2001 as clinic costs salaries and related
expense. After a detailed review of our previous accounting policy and our Clinic Partnerships,
management has determined that reporting such amounts in this line item was incorrect. The effect
of reclassifying the prior period financials statements did not change total assets, shareholders
equity, net income or earnings per share. The minority interests previously recorded as expense in
clinic costs salaries and related, after reclassification, have the effect of increasing
operating income from continuing operations by $243,000 for the three months ended March 31, 2006
and increasing minority interest in subsidiary limited partnerships by $687,000 at March 31, 2006.
In addition, reclassification has been made to prior period amounts to reflect the effects of the
presentation of auction rate securities as marketable securities rather than cash and cash
equivalents in the Consolidated Statement of Cash Flows for the three months March 31, 2006. The
Consolidated Statement of Cash Flows reflects the activity in the marketable securities available
for sale for such period. Since the fair value of the marketable securities available for sale
equals the cost basis, there is no effect on current assets, total assets, net income or
comprehensive income.
In accordance with current accounting literature, the results of operations and closure costs for
the 31 clinics closed in 2006 and the results of operations for the clinic sold in 2006 are
presented as discontinued operations for all periods presented, net of tax benefit.
The following table reconciles the amounts previously reported to the amounts reported in these
financial statements by major line item for the statements of net income and cash flows for the
three months March 31, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2006 |
|
|
|
As Previously |
|
|
|
|
|
|
|
|
|
Reported (1) |
|
|
Reclasses |
|
|
As Reclassed |
|
Statement of Net Income |
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue |
|
$ |
34,656 |
|
|
$ |
(1,153 |
) (2) |
|
$ |
33,503 |
|
Clinic operating costs |
|
|
26,591 |
|
|
|
(1,759 |
) (3) |
|
|
24,832 |
|
Corporate office costs |
|
|
4,515 |
|
|
|
|
|
|
|
4,515 |
|
|
|
|
|
|
|
|
|
|
|
|
Operating income from continuing operations |
|
|
3,550 |
|
|
|
|
|
|
|
4,156 |
|
Interest and investment income, net |
|
|
82 |
|
|
|
|
|
|
|
82 |
|
Loss in unconsolidated joint venture |
|
|
(21 |
) |
|
|
|
|
|
|
(21 |
) |
Minority interest in subsidiary limited partnerships |
|
|
(1,201 |
) |
|
|
(268 |
) |
|
|
(1,469 |
) |
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes from continuing operations |
|
|
2,410 |
|
|
|
|
|
|
|
2,748 |
|
Provision for income taxes |
|
|
926 |
|
|
|
116 |
|
|
|
1,042 |
|
|
|
|
|
|
|
|
|
|
|
|
Net income from continuing operations |
|
|
1,484 |
|
|
|
|
|
|
|
1,706 |
|
Loss (income) from discontinued operations, net of tax |
|
|
|
|
|
|
(222 |
) |
|
|
(222 |
) |
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
1,484 |
|
|
$ |
|
|
|
$ |
1,484 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Statement of Cash Flows |
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
$ |
4,981 |
|
|
$ |
149 |
(4) |
|
$ |
5,130 |
|
Net cash used in investing activities |
|
|
(2,334 |
) |
|
|
(100 |
) (5) |
|
|
(2,434 |
) |
Net cash used in financing activities |
|
|
(1,788 |
) |
|
|
(149 |
) (6) |
|
|
(1,937 |
) |
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents |
|
|
859 |
|
|
|
(100 |
) |
|
|
759 |
|
Cash and cash equivalents beginning of period |
|
|
15,002 |
|
|
|
(2,650 |
) (7) |
|
|
12,352 |
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents end of period |
|
$ |
15,861 |
|
|
$ |
(2,750 |
) |
|
$ |
13,111 |
|
|
|
|
|
|
|
|
|
|
|
Footnotes on following page.
11
|
|
|
(1) |
|
As previously reported in the Companys Form 10Q for the quarterly period ended March 31, 2006. |
|
(2) |
|
Includes revenues related to closed clinics. |
|
(3) |
|
Includes minority interests in subsidiary limited partnerships previously reported as clinic operating costs - |
|
|
|
salaries and related costs of $243,000 and costs related to Discontinued Operations of $1,516,000. |
|
(4) |
|
Includes increase in minority interests in subsidiary limited partnerships previously reported as clinic
operating costs salaries and related costs of $243,000 offset by change in compensation liability of
$94,000.
For clinic partnerships formed after January 18, 2001, earnings allocated to minority interests in
subsidiary limited partnerships that were accrued and not paid were previously included in other liabilities
and the net change was included in net cash provided by operating activities in the statement of cash flows. |
|
(5) |
|
Includes purchase of marketable securities of $100,000. |
|
(6) |
|
Represents distribution paid to minority limited partners for Clinic Partnerships formed after January 18,
2001. |
|
(7) |
|
Represents marketable securities previously reported as cash and cash equivalents. |
Stock Options and Restricted Stock
Effective January 1, 2006, the Company adopted Statement No. 123R, Share-Based Payment (SFAS 123R),
which requires companies to measure and recognize compensation expense for all stock-based payments
at fair value. SFAS 123R was applied on the modified prospective basis. Under the modified
prospective approach, SFAS 123R applies to new awards and to awards that were outstanding on
January 1, 2006 that are subsequently modified, repurchased or cancelled. Under the modified
prospective approach, compensation cost recognized for 2006 includes compensation for all
stock-based payments granted prior to, but not yet vested on January 1, 2006, based on the
grant-date fair value estimated in accordance with the provisions of SFAS 123, and compensation
cost for the stock-based payment granted subsequent to January 1, 2006, based on the grant-date
fair value with the provisions of SFAS 123R. No stock options were granted during the three months
ended March 31, 2007.
The impact of adopting SFAS 123R on January 1, 2006 resulted in lowering net income and net income
per diluted share for the three months ended March 31, 2007 and 2006 by $145,000, or $0.01 per
diluted share, and $137,000, or $0.01 per diluted share, respectively. As of March 31, 2007, the
future pre-tax expense of nonvested stock options is $2.3 million to be recognized in the remainder
of 2007 through 2010.
In the first quarter of 2007, the Company granted 51,000 shares of restricted stock to employees
pursuant to its 1999 Stock Incentive Plan for $0.01 per share. The restricted stock is subject to
continued employment by the employees and will vest in equal installments on the following five
anniversaries of the date of grant. Compensation expense for grants of restricted stock will be
recognized based on the fair value of $14.43 per share on the date of grant. The total
compensation of $0.7 million for these 51,000 shares will be recognized in 2007 through early 2012.
For the first quarter of 2007, compensation expense for restricted stock grants, including shares
of restricted stock granted in 2006, was $21,000. There was no compensation expense related to
restricted stock for the first quarter 2006.
Recently Promulgated Accounting Pronouncements
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements, (SFAS 157) which
addresses how companies should measure fair value when they are required to use a fair value
measure for recognition or disclosure purposes under generally accepted accounting principles
(GAAP). As a result of SFAS 157 there is now a common definition of fair value to be used
throughout GAAP. The FASB believes that the new standard will make the measurement of fair value
more consistent and comparable and improve disclosures about those measures. SFAS 157 is effective
for fiscal years beginning after November 15, 2007. Management is currently evaluating the impact
of the statement on the Company. Management does not believe the adoption of SFAS 157 will have a
material impact on our consolidated financial statements.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and
Financial Liabilities Including an Amendment of FASB Statement No. 115 (SFAS 159), SFAS No.
159 permits entities to choose to measure many financial instruments and certain other items at
fair value and is effective for fiscal years beginning after November 15, 2007, or January 1, 2008
for the Company. Early adoption is permitted as of the beginning of previous fiscal year provided
that the entity makes that choice in the first 120 days of that fiscal year and also elects to
provide the provisions of SFAS No. 157. The Company is in the process of evaluating the impact of
this pronouncement on its consolidated financial statements. Management does not believe the
adoption of SFAS 159 will have a material impact on our consolidated financial statements.
12
2. EARNINGS PER SHARE
The computations of basic and diluted earnings per share for the Company are as follows (in
thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2007 |
|
|
2006 |
|
Numerator: |
|
|
|
|
|
|
|
|
Net income from continuing operations |
|
$ |
1,844 |
|
|
$ |
1,706 |
|
Net loss from discontinued operations |
|
|
(15 |
) |
|
|
(222 |
) |
|
|
|
|
|
|
|
Net income |
|
$ |
1,829 |
|
|
$ |
1,484 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
Denominator for basic earnings per share -
weighted-average shares |
|
|
11,501 |
|
|
|
11,824 |
|
Effect of dilutive securities: |
|
|
|
|
|
|
|
|
Stock options |
|
|
88 |
|
|
|
212 |
|
|
|
|
|
|
|
|
Denominator for diluted earnings per share -
adjusted weighted-average shares and assumed conversions |
|
|
11,589 |
|
|
|
12,036 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share: |
|
|
|
|
|
|
|
|
Basic income from continuing operations |
|
$ |
0.16 |
|
|
$ |
0.14 |
|
Basic loss from discontinued operations |
|
|
|
|
|
|
(0.01 |
) |
|
|
|
|
|
|
|
Total basic earnings per share |
|
$ |
0.16 |
|
|
$ |
0.13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income from continuing operations |
|
$ |
0.16 |
|
|
$ |
0.14 |
|
Diluted loss from discontinued operations |
|
|
|
|
|
|
(0.02 |
) |
|
|
|
|
|
|
|
Total diluted earnings per share |
|
$ |
0.16 |
|
|
$ |
0.12 |
|
|
|
|
|
|
|
|
Options to purchase 456,000 and 125,000 shares for the three months ended March 31, 2007 and
2006, respectively, were excluded from the diluted earnings per share calculations for the
respective periods because the options exercise prices were greater than the average market price
of the common shares during the periods.
3. ACQUISITIONS
Acquisition of Business
On November 17, 2006, the Company acquired a majority interest in an eight-clinic practice located
in Arizona (Arizona Acquisition). The Company acquired a 65% interest with the existing partner
retaining a 35% interest. The Company paid $5,959,000, consisting of a three-year note payable in
the amount of $877,500 and cash of $5,081,500. In addition, the Company incurred $70,000 of
capitalized acquisition costs. The purchase agreement also provides for possible contingent
consideration of up to $1,500,000 based on the achievement of a certain designated level of
operating results with a three-year period following the acquisition. Any contingent payments made
will increase goodwill.
In 2006, the Arizona acquisition resulted in approximately $5.5 million of goodwill which is
deductible for tax purposes. Other assets related to this acquisition included accounts receivable
valued at $546,000, furniture and equipment valued at $78,000, prepaid rental valued at $16,000 and
a non-competition agreement valued at $160,693 which is being amortized over five years. The
Company also assumed certain employee benefits and other liabilities of approximately $113,000 and
recorded minority interests in subsidiary limited partnerships of approximately $184,000.
The Company is permitted to make, and has occasionally made, changes to preliminary purchase price
allocations during the first year after completing an acquisition.
Unaudited proforma consolidated financial information for this acquisition has not been included as
the results were not material to current operations.
13
Acquisitions of Minority Interests
During the first quarter of 2007, the Company purchased the minority interest in three limited
partnerships in separate transactions for an aggregate purchase price of $161,000. The purchases
yielded $129,000 of goodwill related to one of the partnerships and the remaining $32,000
represented payment of undistributed earnings to the minority limited partners.
During 2006, the Company purchased the 35% minority interest in three limited partnerships in
separate transactions for an aggregate purchase price $1.1 million. Under two of the purchase
agreements, the Company may be required to pay contingent consideration of up to $284,000, in
aggregate, based on the achievement of a certain designated level of operating results within a
three-year period following the acquisitions. Any contingent payments made will increase goodwill.
For all minority interest purchases noted above, the Company paid or has agreed to pay to the
minority limited partner any undistributed earnings earned through an agreed date prior to the
purchase date.
The Companys minority interest purchases were accounted for as purchases and accordingly, the
results of operations of the acquired minority interest percentage are included in the accompanying
financial statements from the dates of purchase. In addition, the Company is permitted to make, and
has occasionally made, changes to preliminary purchase price allocations during the first year
after completing the purchase.
The changes in the carrying amount of goodwill consisted of the following (in thousands):
|
|
|
|
|
|
|
Quarter |
|
|
|
Ended |
|
|
|
March 31, |
|
|
|
2007 |
|
Beginning balance |
|
$ |
20,997 |
|
Goodwill acquired during the year |
|
|
129 |
|
Adjustment |
|
|
(44 |
) |
|
|
|
|
Ending balance |
|
$ |
21,082 |
|
|
|
|
|
4. CLOSURE COSTS AND DISCONTINUED OPERATIONS
After a thorough review of the Companys clinics, management decided to close 28 unprofitable
clinics in the third quarter of 2006. Previously, during the second quarter of 2006, three clinics
were closed. The operating results of these 31 locations have been reported as discontinued
operations for all periods presented as required by SFAS 144. The following are the net revenues
and pre-tax losses reported for these locations (in thousands):
|
|
|
|
|
|
|
Quarter |
|
|
Ended |
|
|
March 31, |
|
|
2006 |
Net revenues |
|
$ |
1,153 |
|
Pre-tax loss |
|
$ |
(338 |
) |
The accrual balance at December 31, 2006, which consisted of lease commitments for the closed
clinics, and the accrual balance and activity for the three months ended March 31, 2007 are as
follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec 31, 2006 |
|
|
|
|
|
|
|
|
|
|
Mar 31, 2007 |
|
Type of Cost |
|
Balance |
|
|
Additions |
|
|
Activity |
|
|
Balance |
|
Lease obligations |
|
$ |
829 |
|
|
$ |
24 |
|
|
$ |
(252 |
) |
|
$ |
601 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lease commitments represent the future payments remaining under lease agreements adjusted for
estimated early settlements. The cash flow impact of these 31 clinics is deemed immaterial for the
consolidated statements of cash flows.
14
5. NOTES PAYABLE
Notes payable as of March 31, 2007 and December 31, 2006 consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
2007 |
|
|
2006 |
|
Promissory note payable in quarterly installments of $73,125 plus accrued
interest through November 17, 2009, interest accrues at 7.5% per annum |
|
$ |
804 |
|
|
$ |
877 |
|
Promissory note payable in quarterly installments of $41,667 plus accrued
interest through May 18, 2008, interest accrues at 6% per annum |
|
|
208 |
|
|
|
250 |
|
Promissory note payable in quarterly installments of $25,809 plus accrued
interest through December 19, 2008, interest accrues at 5.75% per annum |
|
|
181 |
|
|
|
232 |
|
|
|
|
|
|
|
|
|
|
|
1,193 |
|
|
|
1,359 |
|
Less current portion |
|
|
(537 |
) |
|
|
(562 |
) |
|
|
|
|
|
|
|
|
|
$ |
656 |
|
|
$ |
797 |
|
|
|
|
|
|
|
|
In connection with the Arizona Acquisition, the Company incurred a note payable in the amount
of $877,500, payable in equal quarterly principal installments of $73,125 beginning March 1, 2007
plus any accrued and unpaid interest. Interest accrues at a fixed rate of 7.5% per annum. The
remaining principal and any accrued and unpaid interest then outstanding is due and payable on
November 17, 2009.
In connection with the acquisition of three physical and occupational therapy clinics located in
New Jersey on May 18, 2005, the Company incurred a note payable in the amount of $500,000, payable
in equal quarterly principal installments of $41,667 beginning September 1, 2005 plus any accrued
and unpaid interest. Interest accrues at a fixed rate of 6% per annum. All outstanding principal
and any accrued and unpaid interest then outstanding is due and payable on May 18, 2008.
In connection with the acquisition of two physical therapy clinics located in Alaska on December
19, 2005, the Company incurred a note payable in the amount of $309,710, payable in equal quarterly
principal installments of $25,809 beginning April 1, 2006 plus any accrued and unpaid interest.
Interest accrues at a fixed rate of 5.75% per annum. All outstanding principal and any accrued and
unpaid interest then outstanding is due and payable on December 19, 2008.
Effective September 30, 2005, the Company entered into an unsecured Credit Agreement (Credit
Agreement). The Credit Agreement, which matures on September 30, 2007, allows the Company to
borrow funds not to exceed at any one time an outstanding balance of $5,000,000 (Commitment).
The outstanding balance bears interest, at the Companys option, at a rate per annum equal to
either the prime rate, as defined in the agreement, or the adjusted LIBOR rate, as defined in the
agreement, plus three-quarters of one percent. The Company is required to pay a commitment fee,
which is paid quarterly in arrears, of 0.20% per annum on the daily average difference between the
Commitment and the outstanding balance. As of the date of this report, there are no funds
outstanding under this Credit Agreement.
15
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
EXECUTIVE SUMMARY
Our Business
We operate outpatient physical and occupational therapy clinics that provide preventive, curative
and post-operative care for a variety of orthopedic-related disorders and sports-related injuries,
treatment for neurologically-related injuries and rehabilitation of injured workers. At March 31,
2007, we operated 293 outpatient physical and occupational therapy
clinics in 41 states. Of these operating clinics, we have developed
274 and acquired 19. During the first quarter of 2007, we added three
new clinics and closed two. To date, we have opened 361 facilities,
acquired 19 clinics, sold seven clinics, closed 76 facilities and
consolidated four clinics with other existing clinics. The average
age of our clinics at March 31, 2007 was 5.4 years.
In addition to our owned clinics, we also manage physical therapy facilities for third parties,
primarily physicians, with three third-party facilities under management as of March 31, 2007.
Selected Operating and Financial Data
During 2006, we closed 31 unprofitable clinics. In accordance with current accounting literature,
the results of operations and closure costs for these 31 clinics and the results of operations for
one clinic sold in 2006 are presented as discontinued operations for all periods presented, net of
the tax benefit. In addition, the prior period financial statements have been reclassified to
conform with the current year presentation of reporting all earnings allocated to the minority
interests limited partners within the line item in the statement of net income entitled minority
interests in subsidiary limited partnerships and of presenting auction rate securities as
marketable securities rather than cash and cash equivalents.
The following table reconciles the amounts previously reported to the amounts reported in these
financial statements by major line item for the statements of net income and cash flows for the
three months ended March 31, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2006 |
|
|
|
As Previously |
|
|
|
|
|
|
|
|
|
Reported (1) |
|
|
Reclasses |
|
|
As Reclassed |
|
Statement of Net Income |
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue |
|
$ |
34,656 |
|
|
$ |
(1,153 |
) (2) |
|
$ |
33,503 |
|
Clinic operating costs |
|
|
26,591 |
|
|
|
(1,759 |
) (3) |
|
|
24,832 |
|
Corporate office costs |
|
|
4,515 |
|
|
|
|
|
|
|
4,515 |
|
|
|
|
|
|
|
|
|
|
|
|
Operating income from continuing operations |
|
|
3,550 |
|
|
|
|
|
|
|
4,156 |
|
Interest and investment income, net |
|
|
82 |
|
|
|
|
|
|
|
82 |
|
Loss in unconsolidated joint venture |
|
|
(21 |
) |
|
|
|
|
|
|
(21 |
) |
Minority interest in subsidiary limited partnerships |
|
|
(1,201 |
) |
|
|
(268 |
) |
|
|
(1,469 |
) |
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes from continuing operations |
|
|
2,410 |
|
|
|
|
|
|
|
2,748 |
|
Provision for income taxes |
|
|
926 |
|
|
|
116 |
|
|
|
1,042 |
|
|
|
|
|
|
|
|
|
|
|
|
Net income from continuing operations |
|
|
1,484 |
|
|
|
|
|
|
|
1,706 |
|
Loss (income) from discontinued operations, net of tax |
|
|
|
|
|
|
(222 |
) |
|
|
(222 |
) |
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
1,484 |
|
|
$ |
|
|
|
$ |
1,484 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Statement of Cash Flows |
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
$ |
4,981 |
|
|
$ |
149 |
(4) |
|
$ |
5,130 |
|
Net cash used in investing activities |
|
|
(2,334 |
) |
|
|
(100 |
) (5) |
|
|
(2,434 |
) |
Net cash used in financing activities |
|
|
(1,788 |
) |
|
|
(149 |
) (6) |
|
|
(1,937 |
) |
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents |
|
|
859 |
|
|
|
(100 |
) |
|
|
759 |
|
Cash and cash equivalents beginning of period |
|
|
15,002 |
|
|
|
(2,650 |
) (7) |
|
|
12,352 |
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents end of period |
|
$ |
15,861 |
|
|
$ |
(2,750 |
) |
|
$ |
13,111 |
|
|
|
|
|
|
|
|
|
|
|
Footnotes on following page.
16
|
|
|
(1) |
|
As previously reported in the Companys Form 10Q for the quarterly period ended March 31, 2006. |
|
(2) |
|
Includes revenues related to closed clinics. |
|
(3) |
|
Includes minority interests in subsidiary limited partnerships previously reported as clinic operating costs - |
|
|
|
salaries and related costs of $243,000 and costs related to Discontinued Operations of $1,516,000. |
|
(4) |
|
Includes increase in minority interests in subsidiary limited partnerships previously reported as clinic
operating costs salaries and related costs of $243,000 offset by change in compensation liability of
$94,000.
For clinic partnerships formed after January 18, 2001, earnings allocated to minority interests in
subsidiary limited partnerships that were accrued and not paid were previously included in other liabilities
and the net change was included in net cash provided by operating activities in the statement of cash flows. |
|
(5) |
|
Includes purchase of marketable securities of $100,000. |
|
(6) |
|
Represents distribution paid to minority limited partners for Clinic Partnerships formed after January 18,
2001. |
|
(7) |
|
Represents marketable securities previously reported as cash and cash equivalents. |
The following table and discussion relates to continuing operations unless otherwise noted. Mature
Clinics in the following discussion relates to clinics opened or acquired before March 31, 2006 and
not closed in 2006.
The following table presents selected operating and financial data that we believe are key
indicators of our operating performance.
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2007 |
|
|
2006 |
|
Number of clinics, at the end of period |
|
|
293 |
|
|
|
266 |
|
Working Days |
|
|
64 |
|
|
|
64 |
|
Average visits per day per clinic |
|
|
19.1 |
|
|
|
20.5 |
|
Total patient visits |
|
|
359,032 |
|
|
|
338,669 |
|
|
|
|
|
|
|
|
|
|
Net patient revenue per visit |
|
$ |
95.47 |
|
|
$ |
97.17 |
|
Statement of operations per visit: |
|
|
|
|
|
|
|
|
Net revenues |
|
$ |
96.43 |
|
|
$ |
98.92 |
|
Salaries and related costs |
|
|
49.90 |
|
|
|
51.04 |
|
Rent, clinic supplies, contract labor and other |
|
|
20.69 |
|
|
|
20.71 |
|
Provision for doubtful accounts |
|
|
1.76 |
|
|
|
1.57 |
|
|
|
|
|
|
|
|
Contribution from clinics |
|
|
24.08 |
|
|
|
25.60 |
|
Corporate office costs |
|
|
12.14 |
|
|
|
13.33 |
|
|
|
|
|
|
|
|
Operating income from continuing operations |
|
$ |
11.94 |
|
|
$ |
12.27 |
|
|
|
|
|
|
|
|
RESULTS OF OPERATIONS
Three Months Ended March 31, 2007 Compared to the Three Months Ended March 31, 2006
|
|
|
Net revenues increased to $34.6 million for the three months ended March 31, 2007 (2007
First Quarter) from $33.5 million for the three months ended March 31, 2006 (2006 First
Quarter) due to a 6.0% increase in patient visits from 339,000 to 359,000 which was
partially offset by a $1.70 decrease from $97.17 to $95.47 in net patient revenue per
visit. Effective January 1, 2007, the reimbursement rate by Medicare for outpatient
rehabilitation was cut by approximately 6.0%. Medicare comprised 19% of the Companys
charges in the 2007 First Quarter. |
|
|
|
|
Net income (inclusive of discontinued operations) was $0.16 per diluted share for the
2007 First Quarter as compared to $0.12 for the 2006 First Quarter. Net income (inclusive
of discontinued operations) for the 2007 First Quarter was $1.8 million versus $1.5 million
for the same period last year. The 2007 First Quarter includes a loss from discontinued
operations of $15,000, versus $0.2 million, or $0.02 per diluted share for the 2006 First
Quarter. Total diluted shares were 11.6 million for the 2007 First Quarter and 12.0
million for the 2006 First Quarter. |
17
Net Patient Revenues
|
|
|
Net patient revenues increased to $34.3 million for the 2007 First Quarter from $32.9
million for the 2006 First Quarter, an increase of $1.4 million, or 4.2%, due to a 6.0%
increase in patient visits to 359,000 which was offset partially by a $1.70 decrease in net
patient revenues per visit to $95.47 from 97.17. |
|
|
|
|
Total patient visits increased 20,000 or 6.0%, to 359,000 for the 2007 First Quarter
from 339,000 for the 2006 First Quarter. The growth in visits was attributable to an
increase of approximately 23,000 visits in clinics opened or acquired between April 1, 2006
and March 31, 2007 (the New Clinics) offset by a slight decrease of 3,000 for Mature
Clinics. The slight visits decline was attributable to clinics located in Michigan as the
rest of the Mature Clinics collectively achieved an increase in same store visits. |
|
|
|
|
Net patient revenues from New Clinics were approximately $2.4 million. The offsetting
decrease of $1.0 million in net patient revenues was from Mature Clinics. Of the $1.0
million decrease, a $0.7 million increase related to clinics opened in the 2006 First
Quarter and a $1.7 million decrease related to clinics opened prior to January 1, 2006
(excluding those clinics closed in 2006). |
Net patient revenues are based on established billing rates less allowances and discounts for
patients covered by contractual programs and workers compensation. Net patient revenues reflect
contractual and other adjustments relating to patient discounts from certain payors. Payments
received under these programs are based on predetermined rates and are generally less than the
established billing rates of the clinics.
Clinic Operating Costs
Clinic operating costs as a percent of net revenues were 75.0% for the 2007 First Quarter and 74.1%
for the 2006 First Quarter.
Clinic Operating Costs Salaries and Related Costs
Salaries and related costs increased to $17.9 million for the 2007 First Quarter from $17.3
million for the 2006 First Quarter, an increase of $0.6 million, or 3.6%. Of the $0.6 million
increase, costs of $1.2 million were incurred at the New Clinics which was offset by a
decrease of $0.6 million at the Mature Clinics. Salaries and related costs as a percent of
net revenues remained at 52.0% for the 2007 First Quarter and 2006 First Quarter.
Clinic Operating Costs Rent, Clinic Supplies, Contract Labor and Other
Rent, clinic supplies, contract labor and other increased to $7.4 million for the 2007 First
Quarter from $7.0 million for the 2006 First Quarter, an increase of $0.4 million, or 5.9%.
Approximately $0.7 million was incurred at the New Clinics and a decrease of $0.3 million was
achieved at the Mature Clinics. Rent, clinic supplies, contract labor and other as a percent
of net revenues was 21.5% for the 2007 First Quarter and 20.9% for the 2006 First Quarter.
Clinic Operating Costs Provision for Doubtful Accounts
The provision for doubtful accounts increased to $0.6 million for the 2007 First Quarter from
$0.5 million for the 2006 First Quarter, an increase of $0.1 million or 18.6%. The provision
for doubtful accounts as a percent of net patient revenues was 1.8% for the 2007 First Quarter
and 1.6% for the 2006 First Quarter. Our allowance for bad debts as a percent of total patient
accounts receivable was 7.1% at March 31, 2007, as compared to 6.8% at December 31, 2006.
Corporate Office Costs
Corporate office costs, consisting primarily of salaries and benefits of corporate office
personnel, rent, insurance costs, depreciation and amortization, travel, legal, professional, and
recruiting fees, decreased slightly to $4.4 million, or 12.6% of net revenues, for the 2007 First
Quarter from $4.5 million, or 13.5% or net revenues, for the 2006 First Quarter.
Minority Interests in Earnings of Subsidiary Limited Partnerships
Minority interests in earnings of subsidiary limited partnerships decreased to $1.3 million for the
2007 First Quarter from $1.5 million for the 2006 First Quarter. Minority interest as a percentage
of operating income before corporate office costs decreased to 15.2% for the 2007 First Quarter as
compared to 16.9% for the 2006 First Quarter. Since the 2006 First Quarter, the Company has
purchased the minority interest of five limited partnerships.
18
Provision for Income Taxes
The provision for income taxes increased to $1.2 million for the 2007 First Quarter from $1.0
million for the 2006 First Quarter, an increase of approximately $0.2 million, or 12.2% as a result
of higher pre-tax income before discontinued operations. During the 2007 First Quarter, we accrued
state and federal income taxes at an effective tax rate of 38.8% versus 37.9% for the 2006 First
Quarter.
Loss from Discontinued Operations
During 2006, the Company closed 31 clinics and sold one. For those clinics, the Company incurred
$15,000, net of tax benefit, in additional closure costs during the 2007 First Quarter and incurred
loss from operations from those clinics of $222,000, net of tax benefit, during the 2006 First
Quarter. The operating results of these two clinics were not material to the operations of the
Company, and therefore, the results of these clinics were not classified and reported as
discontinued operations.
LIQUIDITY AND CAPITAL RESOURCES
We believe that our business is generating sufficient cash flow from operating activities to allow
us to meet our short-term and long-term cash requirements. At March 31, 2007, we had $14.6
million in cash and cash equivalents and marketable securities available for sale (Cash
Equivalents Available) compared to $11.5 million at December 31, 2006. Although the start-up costs
associated with opening new clinics, and our planned capital expenditures are significant, we
believe that our Cash Equivalents Available are sufficient to fund the working capital needs of our
operating subsidiaries, payment of clinic closure costs accrued, future clinic development and
investments through at least March 2008. Any large acquisition would probably be financed with
debt. Included in cash and cash equivalents at March 31, 2007 were $6.6 million in a money market
fund and $1.7 million in investments which include short-term high-grade commercial paper (credit
rating of A1/P1 or better), municipal obligations and government sponsored enterprise investments.
Cash Equivalents Available increased $3.1 million from December 31, 2006 to March 31, 2007 due
primarily to cash provided by operating activities of $5.4 million, offset primarily by $0.8
million used for the purchase of fixed assets, $1.5 million used for distributions to minority
investors in subsidiary limited partnerships, $0.2 million used for payment of principal on notes
payable, and $0.1 million used for the purchase of minority interests.
At March 31, 2007, we had $0.6 million in accrued expenses related to lease commitments for closed
clinics. This amount will be paid over the next twelve months.
Effective September 30, 2005, the Company entered into an unsecured Credit Agreement. The Credit
Agreement, which matures on September 30, 2007, allows the Company to borrow funds not to exceed at
any one time an outstanding principal balance of $5,000,000 (Commitment). The outstanding
balance bears interest, at the Companys option, at a rate per annum equal to either the prime
rate, as defined in the agreement, or the adjusted LIBOR rate, as defined in the agreement, plus
three-quarters of one percent. The Company is required to pay a commitment fee, which is paid
quarterly in arrears, of 0.20% per annum on the daily average difference between the Commitment and
the outstanding balance. As of the date of this report, there were no funds outstanding under the
Credit Agreement.
Historically, we have generated sufficient cash from operations to fund our development activities
and cover operational needs. We generally develop new clinics rather than acquire them, which
requires less capital. We plan to continue developing new clinics and make additional acquisitions
in select markets. We have from time to time purchased the minority interests of limited partners
in our clinic partnerships. We may purchase additional minority interests in the future. Generally,
any acquisition or purchase of minority interests is expected to be accomplished using a
combination of cash and notes. We believe that existing funds and the availability of funds under
the Credit Agreement, supplemented by cash flows from existing operations, will be sufficient to
meet our current operating needs, development plans and any purchases of minority interests through
at least March 2008. Any large acquisition would probably be financed with debt.
The Company makes reasonable and appropriate efforts to collect its accounts receivable, including
applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims
are submitted to payors daily, weekly or monthly in accordance with our policy or payors
requirements. When possible, we submit our claims electronically. The collection process is time
consuming and typically involves the submission of claims to multiple payors whose payment of
claims may be dependent upon the payment of another payor. Claims under litigation and vehicular
incidents can take a year or longer to collect. Medicare and other payor claims relating to new
clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six to 12
months. When all reasonable internal collection efforts have been exhausted, accounts are written
off prior to sending them to outside collection firms. With managed care, commercial health plans
and self-pay payor type receivables, the write-off generally occurs after the account receivable
has been outstanding for 120 days.
19
In conjunction with the acquisition of an eight-clinic practice in Arizona in November 2006, we
entered into a note payable with the sellers in the amount of $877,500 payable in equal quarterly
principal installments of $73,125, beginning March 1, 2007, plus any accrued and unpaid interest.
Interest accrues at a fixed rate of 7.5% per annum. The remaining principal and any accrued and
unpaid interest then outstanding is due and payable on the third anniversary of the note, November
17, 2009. The purchase agreement also provides for possible contingent consideration of up to
$1,500,000 based on the achievement of a certain designated level of operating results within a
three-year period following the acquisition. In addition, we assumed leases with remaining terms
ranging from one to five years for six of the eight operating facilities. With respect to the two
remaining leased facilities, one is being leased on a month-to-month basis and the other was
renewed for three years effective February 1, 2007.
In conjunction with the acquisition of the three-clinic practice in New Jersey in May 2005, we
entered into a note payable with the sellers in the amount of $500,000 payable in equal quarterly
principal installments of $41,667, beginning September 1, 2005, plus any accrued and unpaid
interest. Interest accrues at a fixed rate of 6% per annum. All outstanding principal and any
accrued and unpaid interest then outstanding is due and payable on the third anniversary of the
note, May 18, 2008. The purchase agreement also provides for possible contingent consideration of
up to $650,000 based on the achievement of a certain designated level of operating results within a
three-year period following the acquisition. In addition, we entered into a 5-year lease for each
of the three facilities. In July 2006, we paid $90,000 additional consideration related to this
acquisition upon achievement of the predefined operating results for the first year and such amount
was added to goodwill.
In conjunction with the acquisition of the two-clinic practice in Alaska in December 2005, we
entered into a note payable with the sellers in the amount of $309,710 payable in equal quarterly
principal installments of $25,809, beginning April 1, 2006, plus any accrued and unpaid interest.
Interest accrues at a fixed rate of 5.75% per annum. All outstanding principal and any accrued and
unpaid interest then outstanding is due and payable on the third anniversary of the note, December
19, 2008. The purchase agreement also provides for possible contingent consideration of up to
$325,000 based on the achievement of a certain designated level of operating results within a
three-year period following the acquisition. In addition, we entered into a 5-year lease for one
of the facilities and assumed a lease expiring September 30, 2009 on the other facility.
Since September 2001, the Board of Directors (Board) has authorized the Company to purchase, in
the open market or in privately negotiated transactions, up to 2,250,000 shares of its common
stock. As of March 31, 2007, there were approximately 50,000 shares remaining that could be
purchased under these programs. Since there is no expiration date for these share repurchase
programs, additional shares may be purchased from time to time in the open market or private
transactions depending on price, availability and the Companys cash position. Shares purchased are
held as treasury shares and may be used for such valid corporate purposes or retired as the Board
considers advisable. The Company did not purchase any shares of its common stock during the 2007
First Quarter.
FACTORS AFFECTING FUTURE RESULTS
Clinic Development
As of March 31, 2007, we had 293 clinics in operation, three of which were opened in the 2007 First
Quarter. We expect to incur initial operating losses from new clinics opened in 2007 and late 2006.
Generally, we experience losses during the initial period of a new clinics operation.
Operating margins for newly opened clinics tend to be lower than for more seasoned clinics
because of start-up costs and lower patient visits and revenues. Patient visits and revenues
gradually increase in the first year of operation, as patients and referral sources become aware of
the new clinic. Revenues typically continue to increase during the two to three years following the
first anniversary of a clinic opening. Based on the historical performance of our new clinics,
generally the clinics opened in late 2006 would favorably impact our results of operations
beginning in late 2007.
20
FORWARD LOOKING STATEMENTS
We make statements in this report that are considered to be forward-looking statements within the
meaning under Section 21E of the Securities Exchange Act of 1934. These statements contain
forward-looking information relating to the financial condition, results of operations, plans,
objectives, future performance and business of our Company. These statements (often using words
such as believes, expects, intends, plans, appear, should and similar words) involve
risks and uncertainties that could cause actual results to differ materially from those we project.
Included among such statements are those relating to opening new clinics, availability of personnel
and the reimbursement environment. The forward-looking statements are based on our current views
and assumptions and actual results could differ materially from those anticipated in such
forward-looking statements as a result of certain risks, uncertainties, and factors, which include,
but are not limited to:
|
|
|
revenue and earnings expectations; |
|
|
|
|
general economic, business, and regulatory conditions including federal and state regulations; |
|
|
|
|
availability and cost of qualified physical and occupational therapists; |
|
|
|
|
salary costs and personnel productivity; |
|
|
|
|
failure of our clinics to maintain their Medicare certification status or changes in Medicare guidelines; |
|
|
|
|
competitive and/or economic conditions in our markets which may require us to close
certain clinics and thereby incur closure costs and losses including the possible
write-down or write-off of goodwill; |
|
|
|
|
changes in reimbursement rates or payment methods from third party payors including
governmental agencies and deductibles and co-pays owed by patients; |
|
|
|
|
maintaining adequate internal controls; |
|
|
|
|
availability, terms, and use of capital; |
|
|
|
|
future acquisitions; and |
|
|
|
|
weather and other seasonal factors. |
Many factors are beyond our control.
Given these uncertainties, you should not place undue reliance on our forward-looking statements.
Please see the other sections of this report and our other periodic reports filed with the
Securities and Exchange Commission (the SEC) for more information on these factors. Our
forward-looking statements represent our estimates and assumptions only as of the date of this
report. Except as required by law, we are under no obligation to update any forward-looking
statement, regardless of the reason the statement is no longer accurate.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts,
futures contracts or the like. We have no material amount of debt.
ITEM 4. CONTROLS AND PROCEDURES.
(a) Evaluation of Disclosure Controls and Procedures
As of the last day of the period covered by this report, we carried out an evaluation, under the
supervision and with the participation of our principal executive officer and principal financial
officer, of the effectiveness of the design and operation of our disclosure controls and
procedures. Based on this evaluation, our principal executive officer and principal financial
officer concluded that our disclosure controls and procedures are effective in ensuring that
information required to be disclosed in the reports that we file or submit under the Securities
Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods
specified in the SECs rules and forms and that such information is accumulated and communicated to
our management, including our principal executive officer and principal financial officer, or
persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure.
(b) Changes in Internal Control
There have been no changes in our internal control over financial reporting during our last fiscal
quarter that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.
21
PART II OTHER INFORMATION
ITEM 6. EXHIBITS.
(a) Exibits
|
|
|
EXHIBIT |
|
|
NO. |
|
DESCRIPTION |
|
|
|
31.1* |
|
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer |
|
|
|
31.2* |
|
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer |
|
|
|
31.3* |
|
Rule 13a-14(a)/15d-14(a) Certification of Corporate Controller |
|
|
|
32* |
|
Certification Pursuant to 18 U.S.C 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on our behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
U.S. PHYSICAL THERAPY, INC.
|
|
Date: May 9, 2007 |
By: |
/s/ LAWRANCE W. MCAFEE
|
|
|
|
Lawrance W. McAfee |
|
|
|
Chief Financial Officer |
|
|
|
(duly authorized officer and principal financial
and accounting officer) |
|
|
|
|
|
|
By: |
/s/ JON C. BATES
|
|
|
|
Jon C. Bates |
|
|
|
Vice President/Corporate Controller |
|
22
INDEX OF EXHIBITS
|
|
|
EXHIBIT |
|
|
NO. |
|
DESCRIPTION |
|
|
|
31.1* |
|
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer |
|
|
|
31.2* |
|
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer |
|
|
|
31.3* |
|
Rule 13a-14(a)/15d-14(a) Certification of Corporate Controller |
|
|
|
32* |
|
Certification Pursuant to 18 U.S.C 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 |
23